Clinical Trial Update: Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®

View source ↗

Summary

Observational study update evaluating the safety of NovoMix 30 FlexPen, sponsored by Novo Nordisk A/S, with completion reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoMix 30 FlexPen (insulin lispro protamine suspension)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Status: COMPLETED